|
Link to IMF Tokyo Seminar Announcement
| PROGRAM AGENDA |
| 9:00 to 9:10 |
Opening Remarks
Susie Novis
President, International Myeloma Foundation
|
| 9:20 to 9:40 |
Standard Treatment of Multiple Myeloma in the USA
Brian G.M. Durie, M.D.
Cedars-Sinai Comprehensive Cancer Center
|
| 9:50 to 10:10 |
Standard Treatment of Multiple Myeloma in Japan
Shuji Ozaki, M.D.
Tokushima University Hospital
Division of Transfusion Medicine
First Department of Internal Medicine
|
| 10:10 to 10:30 |
Break |
| 10:30 to 10:50 |
Anticancer Drug Treatment: Chemotherapy and Thalidomide Therapies
Yutaka Hattori M.D., Ph.D.
Division of Hematology, Department of Medicine
Keio University School of Medicine
|
| 11:00 to 11:20 |
Transplant Treatment: Bone Marrow Transplantation and Peripheral Blood Stem Cell Transplantation
Chihiro Shimazaki, M.D.
Division of Hematology
Kyoto Prefectural University of Medicine
|
| 11:20-13:00 |
Lunch Break |
| 13:00 to 13:20 |
Treatment of Hypercalcaemia and Osteolytic Lesion in Multiple Myeloma
Kiyoshi Nakatsuka, M.D.
Department of Metabolism, Endocrinology & Molecular Medicine
Osaka City University Graduate School of Medicine
|
| 13:30-13:50 |
Orthopedic Treatment of Bone Lesion
Shinjiro Takata, M.D., Ph.D.
Department of Orthopedics
The University of Tokushima School of Medicine
|
| 13:50-14:10 |
Break |
| 14:10 to 14:30 |
What Clinical Trial Participants Need to Know
Yasuo Ohashi, Ph.D.
Biostatistics/Epidemiology and Preventive Health Sciences
School of Health Sciences and Nursing
University of Tokyo
Japan Clinical Research Support Unit
|
| 14:40 to 15:00 |
Clinical Trials of Thalidomide Therapy in Japan and Their Safety Measures
Naokata Shimizu, M.D., Ph.D.
The Organization for Pharmaceutical Safety and Research (OPSR/Kiko)
Teikyo University Medical Department
|
| 15:00 to 15:20 |
Break |
| 15:20 to 16:10 |
Recent Progress in Reduced-Intensity Stem-Cell Transplantation (RIST)
Masahiro Kami, M.D.
National Cancer Central Hospital
Stem Cell Transplantation Unit
|
| 15:50 to 15:40 |
New Medicine: Velcade, Revimid, Trisenox, etc.
Brian G.M. Durie, M.D.
|
| 16:10 to 16:50 |
Questions and Answers |
| 16:50 to 17:00 |
Closing Remarks
Susie Novis
President, International Myeloma Foundation |
| 17:00 to 19:00 |
Reception |
At the same time as the lectures, consultation booths will be open for participants to meet with experts:
- Medical consultation booths for second opinion applicants
- Clinical trial consultation booths for prospective participants
- IMF-Japan booth to provide information and to help enroll applicants in support groups
Link to IMF Tokyo Seminar Announcement
CONTACT INFORMATION:
International Myeloma Foundation
Tokyo Representative Office
OKUBO, Ikumi (Ms)
65-28 Midoricho, Hachioji
Tokyo, 193-0932 Japan
e-mail: okuboikumi@nifty.com
Phone: +81(426)24-9848
Fax: +81(426)24-9864
|
print